skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines gefitinibQuestion & answer

gefitinib · Medicine question

What is the mean terminal half-life of gefitinib in cancer patients?

iatroX medicinesPublished 8 November 2026

The answer

Answer

The mean terminal half-life of gefitinib in cancer patients is 41 hours.

Sources for this answer

Iressa 250mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 18Document updated 30 March 2023

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

gefitinib

More questions about gefitinib

What is the shelf life of Iressa (gefitinib) 250 mg film-coated tablets?What type of lung cancer is Iressa (gefitinib) indicated to treat in adults?Can gefitinib be used during pregnancy?Can Iressa (gefitinib) 250 mg film-coated tablets dispersed in water be administered through a nasogastric or gastrostomy tube?How are Iressa (gefitinib) 250 mg film-coated tablets packaged?How can gefitinib affect the ability to drive or use machines?

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the gefitinib guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX